Incyte's Zynyz Gains EU Approval for SCAC, Marking First Immunotherapy Advance in Decades
Event summary
- Incyte's Zynyz (retifanlimab) received European Commission (EC) approval for first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with carboplatin and paclitaxel.
- The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in January 2026.
- Clinical trial data (POD1UM-303/InterAACT2) demonstrated a 37% reduction in the risk of progression or death (P=0.0006) with the Zynyz combination.
- Zynyz is the first PD-1 immunotherapy approved in Europe in this first-line setting, and the second indication for the drug in Europe (previously approved for Merkel cell carcinoma).
The big picture
The approval of Zynyz represents a significant advancement in treating SCAC, a rare cancer with limited therapeutic options. This marks a rare instance of a new immunotherapy entering a first-line setting for a rare cancer, highlighting the unmet need and potential for targeted therapies. Incyte's collaboration with MacroGenics has yielded a valuable asset, but the company will need to navigate a complex regulatory and commercial landscape to maximize its return on investment.
What we're watching
- Market Adoption
- The speed of uptake by clinicians in Europe will be crucial, given the rarity of SCAC and the need for patient education regarding this new treatment paradigm.
- Competitive Landscape
- While Zynyz holds a first-mover advantage, other pharmaceutical companies will likely explore combination therapies and novel approaches for SCAC, potentially eroding market share over time.
- Safety Profile
- Continued monitoring of the safety profile, particularly concerning the 47% serious adverse reaction rate, will be essential to ensure long-term patient outcomes and maintain regulatory support.
Related topics